Literature DB >> 22025283

Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Raphaëlle Duprez1, Paul M Wilkerson1, Magali Lacroix-Triki1,2, Maryou B Lambros1, Alan MacKay1, Roger A'Hern3, Arnaud Gauthier1,4, Vidya Pawar1, Pierre-Emanuel Colombo1, Frances Daley1, Rachael Natrajan1, Eric Ward1, Gaëtan MacGrogan5, Flavie Arbion6, Patrick Michenet7, Britta Weigelt8, Anne Vincent-Salomon4, Jorge S Reis-Filho1.   

Abstract

Papillary carcinomas are a special histological type of breast cancer and have a relatively good outcome. We characterized the genomic and phenotypic characteristics of papillary carcinomas to determine whether they would constitute an entity distinct from grade- and oestrogen receptor (ER)-matched invasive ductal carcinomas of no special type (IDC-NSTs). The phenotype of 63 papillary carcinomas of the breast and grade- and ER-matched IDC-NSTs was determined by immunohistochemistry. DNA of sufficient quality was extracted from 49 microdissected papillary carcinomas and 49 microdissected grade- and ER-matched IDC-NSTs. These samples were subjected to high-resolution microarray-based comparative genomic hybridization (aCGH) and Sequenom MassARRAY sequencing analysis of 19 known oncogenes. Papillary carcinomas were predominantly of low histological grade, expressed immunohistochemical markers consistent with a luminal phenotype, and a lower rate of lymph node metastasis and p53 expression than grade- and ER-matched IDC-NSTs. Papillary carcinomas displayed less genomic aberrations than grade- and ER-matched IDC-NSTs; however, the patterns of gene copy number aberrations found in papillary carcinomas were similar to those of ER- and grade-matched IDC-NSTs, including 16q losses. Furthermore, PIK3CA mutations were found in 43% and 29% of papillary carcinomas and grade- and ER-matched IDC-NSTs, respectively. The genomic profiles of encapsulated, solid and invasive papillary carcinomas, the three morphological subtypes, were remarkably similar. Our results demonstrate that papillary carcinomas are a homogeneous special histological type of breast cancer. The similarities in the genomic profiles of papillary carcinomas and grade- and ER-matched IDC-NSTs suggest that papillary carcinomas may be best positioned as part of the spectrum of ER-positive breast cancers, rather than as a distinct entity. Furthermore, the good prognosis of papillary carcinomas may stem from the low rates of lymph node metastasis and p53 expression, low number of gene copy number aberrations and high prevalence of PIK3CA mutations.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025283      PMCID: PMC4962905          DOI: 10.1002/path.3032

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  78 in total

1.  Resolving the resolution of array CGH.

Authors:  Bradley P Coe; Bauke Ylstra; Beatriz Carvalho; Gerrit A Meijer; Calum Macaulay; Wan L Lam
Journal:  Genomics       Date:  2007-02-02       Impact factor: 5.736

2.  Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Authors:  Hege G Russnes; Hans Kristian Moen Vollan; Ole Christian Lingjærde; Alexander Krasnitz; Pär Lundin; Bjørn Naume; Therese Sørlie; Elin Borgen; Inga H Rye; Anita Langerød; Suet-Feung Chin; Andrew E Teschendorff; Philip J Stephens; Susanne Månér; Ellen Schlichting; Lars O Baumbusch; Rolf Kåresen; Michael P Stratton; Michael Wigler; Carlos Caldas; Anders Zetterberg; James Hicks; Anne-Lise Børresen-Dale
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

3.  Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas.

Authors:  Cheryl B Hill; I-Tien Yeh
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

4.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH.

Authors:  R Roylance; P Gorman; T Papior; Y-L Wan; M Ives; J E Watson; C Collins; N Wortham; C Langford; H Fiegler; N Carter; C Gillett; P Sasieni; S Pinder; A Hanby; I Tomlinson
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

6.  Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.

Authors:  Agnès Burniat; Ling Jin; Vincent Detours; Natacha Driessens; Jean-Christophe Goffard; Massimo Santoro; Jay Rothstein; Jacques E Dumont; Françoise Miot; Bernard Corvilain
Journal:  Endocrinology       Date:  2008-06-26       Impact factor: 4.736

7.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.

Authors:  Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

8.  Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.

Authors:  Britta Weigelt; Felipe C Geyer; Hugo M Horlings; Bas Kreike; Hans Halfwerk; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2009-07-24       Impact factor: 7.842

9.  BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.

Authors:  S-J Dawson; N Makretsov; F M Blows; K E Driver; E Provenzano; J Le Quesne; L Baglietto; G Severi; G G Giles; C A McLean; G Callagy; A R Green; I Ellis; K Gelmon; G Turashvili; S Leung; S Aparicio; D Huntsman; C Caldas; P Pharoah
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

10.  Malignant myoepithelial cells are associated with the differentiated papillary structure and metastatic ability of a syngeneic murine mammary adenocarcinoma model.

Authors:  Viviana Bumaschny; Alejandro Urtreger; Miriam Diament; Martín Krasnapolski; Gabriel Fiszman; Slobodanka Klein; Elisa Bal de Kier Joffé
Journal:  Breast Cancer Res       Date:  2004-01-15       Impact factor: 6.466

View more
  21 in total

1.  Intracystic papillary carcinoma of the breast: A SEER database analysis of implications for therapy.

Authors:  Harveshp Mogal; Doris R Brown; Scott Isom; Kayla Griffith; Marissa Howard-McNatt
Journal:  Breast       Date:  2016-04-04       Impact factor: 4.380

2.  PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Authors:  Rita A Sakr; Britta Weigelt; Sarat Chandarlapaty; Victor P Andrade; Elena Guerini-Rocco; Dilip Giri; Charlotte K Y Ng; Catherine F Cowell; Neal Rosen; Jorge S Reis-Filho; Tari A King
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

3.  Intracystic papillary carcinoma of breast: interrelationship with in situ and invasive carcinoma and a proposal of pathogenesis: array comparative genomic hybridization study of 14 cases.

Authors:  Thaer Khoury; Qiang Hu; Song Liu; Jianmin Wang
Journal:  Mod Pathol       Date:  2013-08-02       Impact factor: 7.842

Review 4.  Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy.

Authors:  Edi Brogi; Melissa Krystel-Whittemore
Journal:  Mod Pathol       Date:  2020-10-26       Impact factor: 7.842

Review 5.  Papillary neoplasms of the breast-reviewing the spectrum.

Authors:  Timothy Kwang Yong Tay; Puay Hoon Tan
Journal:  Mod Pathol       Date:  2021-01-18       Impact factor: 7.842

6.  Functional characterization of the 19q12 amplicon in grade III breast cancers.

Authors:  Rachael Natrajan; Alan Mackay; Paul M Wilkerson; Maryou B Lambros; Daniel Wetterskog; Monica Arnedos; Kai-Keen Shiu; Felipe C Geyer; Anita Langerød; Bas Kreike; Fabien Reyal; Hugo M Horlings; Marc J van de Vijver; Jose Palacios; Britta Weigelt; Jorge S Reis-Filho
Journal:  Breast Cancer Res       Date:  2012-03-20       Impact factor: 6.466

7.  Molecular characterisation of cell line models for triple-negative breast cancers.

Authors:  Anita Grigoriadis; Alan Mackay; Elodie Noel; Pei Jun Wu; Rachel Natrajan; Jessica Frankum; Jorge S Reis-Filho; Andrew Tutt
Journal:  BMC Genomics       Date:  2012-11-14       Impact factor: 3.969

8.  Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Authors:  Charlotte K Y Ng; Luciano G Martelotto; Arnaud Gauthier; Huei-Chi Wen; Salvatore Piscuoglio; Raymond S Lim; Catherine F Cowell; Paul M Wilkerson; Patty Wai; Daniel N Rodrigues; Laurent Arnould; Felipe C Geyer; Silvio E Bromberg; Magali Lacroix-Triki; Frederique Penault-Llorca; Sylvia Giard; Xavier Sastre-Garau; Rachael Natrajan; Larry Norton; Paul H Cottu; Britta Weigelt; Anne Vincent-Salomon; Jorge S Reis-Filho
Journal:  Genome Biol       Date:  2015-05-22       Impact factor: 13.583

Review 9.  Breast carcinomas of low malignant potential.

Authors:  Stuart J Schnitt; Falko Fend; Thomas Decker
Journal:  Virchows Arch       Date:  2021-07-22       Impact factor: 4.064

10.  In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

Authors:  Michalina Janiszewska; Lin Liu; Vanessa Almendro; Yanan Kuang; Cloud Paweletz; Rita A Sakr; Britta Weigelt; Ariella B Hanker; Sarat Chandarlapaty; Tari A King; Jorge S Reis-Filho; Carlos L Arteaga; So Yeon Park; Franziska Michor; Kornelia Polyak
Journal:  Nat Genet       Date:  2015-08-24       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.